Companies That Exploit Animals ©2019 Crueltyfreeinvesting.Org Title Stock Exchange Stock Symbol Animal Usage 1-800 FLOWERS.COM, Inc
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
Security Master Symbol Description a AGILENT TECHNOLOGIES INC AA
*The information contained herein is believed to Security Master be reliable but is neither guaranteed by EQIS Capital Management, Inc. its principles nor any affiliated EQIS companies. This information is Symbol Description intended for the exclusive use of investment Adviser Representative. This list is subject to A AGILENT TECHNOLOGIES INC change. AA ALCOA CORP COM Advisor Services are offered through EQIS AAAAX DEUTSCHE ALTERNATIVE ASSET ALLOCATION FU Capital Management, Inc. an SEC Registered AAAP ADVANCED ACCELERATOR APPLIC SPONSORED AD Investment Adviser. For information purposes AAASX DEUTSCHE ALTERNATIVE ASSET ALLOCATION F only, not for public distribution. AABPX AMERICAN BEACON BALANCED INVESTOR AAC AAC HLDGS INC COM AACFX AIM CHINA A AADAX AIM GROWTH ALLOCATION CLASS A AADEX AMERICAN BEACON LARGE CAP VALUE INSTL AADR ADVISORSHARES WCM/BNY MLNFCSD GR ADR ETF AAGIY AIA GROUP LTD SPONS ADR AAGPX AMERICAN BEACON LARGE CAP VALUE INVESTOR AAIFX CROW POINT ALTERNATIVE INCOME FUND AAIPX AMERICAN BEACON INTERNATIONAL EQUITY INV AAL AMERICAN AIRLS GROUP INC COM AAMC ALTISOURCE ASSET MGMT CORP COM AAME ATLANTIC AMERN CORP AAN AARONS, INC. CL A AAOI APPLIED OPTOELECTRONICS INC COM AAON AAON INC PAR $0.004 AAP ADVANCED AUTO PARTS INC AAPC ATLANTIC ALLIANCE PARTNER CORP SHS AAPL APPLE INC COM AAT AMERICAN ASSETS TR INC COM AAU ALMADEN MINERALS LTD AAV ADVANTAGE OIL & GAS LTD AAWW ATLAS AIR WORLDWIDE HLDGS INC COM NEW AAXJ ISHARES MSCI ALL COUNTRY ASIA EX JAPAN I AB ALLIANCEBERNSTEIN HOLDING LP UNIT LTD PA ABAC AOXIN TIANLI GROUP INC NEW -
BIOWORLD TODAY Inquiry
BIOWORLDTM TODAY THE DAILY BIOPHARMACEUTICAL NEWS SOURCE JUNE 30 , 2016 BIOTECH’S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS VOLUME 27, NO. 126 LIPID JAM NOT OVER EASILY STOPPED FOR FUTILITY Waffle house? FDA Galena Biopharma implodes as PRESENT review fidgets endpoint, puts cancer vaccine Neuvax future in doubt outcome details; By Jennifer Boggs, Managing Editor Esperion grilled on holdup With the bulk of Galena Biopharma Inc.’s value riding on cancer vaccine Neuvax By Randy Osborne, Staff Writer (nelipepimut-S), the firm’s shares predictably plunged to a new 52-week low Wednesday as an independent data monitoring committee (IDMC) recommended the Analysts had plenty of questions but PRESENT phase III study in breast cancer be stopped for futility following a planned Esperion Therapeutics Inc. offered few interim analysis. But it’s the troubling language in the IDMC’s letter, suggesting the answers regarding the FDA’s stalling on placebo arm might actually have bested the treatment arm, that could signal the end oral, once-daily bempedoic acid (ETC- of the road for Neuvax. 1002) for lipid lowering, after the agency See Galena, page 3 See Esperion, page 4 CHINA DEALS AND M&A IN THE CLINIC Pfizer invests in Asia Merck strikes cancer SUPER ‘NOVA’ with $350M biotech vaccines deal with Tesaro shares blast plant in Hangzhou Moderna, delivering off as niraparib hits By Haky Moon, Staff Writer $200M up front PFS in ovarian cancer HONG KONG – China’s economy may By Michael Fitzhugh, Staff Writer By Marie Powers, News Editor be slowing down, but multinationals Findings from the phase III NOVA trial are positioning themselves to leverage Cancer vaccines tailored to fit tumor- specific profiles are at the heart of a new of niraparib in women with recurrent it as best they can while navigating a ovarian cancer blasted shares of still-complex regulatory environment. -
Initiation of Francis Trial
August 25‚ 2008 ANTHERA PHARMACEUTICALS ADVANCES GLOBAL DEVELOPMENT STRATEGY FOR VARESPLADIB IN PATIENTS WITH ACUTE CORONARY SYNDROME WITH THE INITIATION OF FRANCIS TRIAL SAN MATEO, CA – August 25, 2008 – Anthera Pharmaceuticals Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced the initiation of the FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression) clinical trial designed to examine the impact of varespladib when administered to patients within 96 hours of an Acute Coronary Syndrome (ACS) event. The FRANCIS trial is designed to assess the impact of oral varespladib on known biological markers of cardiovascular risk. It will enroll up to 500 patients that will be treated for a minimum of six months. The study will be conducted at sites in North America and Europe. FRANCIS will provide insight into the prevention of secondary Major Adverse Cardiovascular Events (MACE) over the duration of the trial. In this study, MACE is defined as a composite endpoint consisting of cardiovascular death, non-fatal stroke, non-fatal myocardial infarction, unstable angina, and a subset of revascularization following the initial event. During the course of the study, patients will receive therapeutic standard of care in addition to high dose Lipitor ® (atorvastatin). In previous clinical trials, varespladib, a potent and highly selective inhibitor of secretory phospholipase A 2 (sPLA 2), has demonstrated marked improvements in independent markers of cardiovascular risk including, a near complete suppression of the target enzyme sPLA 2, a clinically meaningful and statistically significant reduction in “bad” LDL cholesterol, and a reduction in C-reactive protein, a known marker of inflammation. -
Tetraphase Pharmaceuticals, Inc
WBB Securities, LLC Steve Brozak, DMH [email protected] (908) 518-7610 Tetraphase Pharmaceuticals, Inc. (NasdaqGS: TTPH) Initiating Coverage Initiating Coverage with a Speculative Buy Rating February 22, 2018 and a 12-Month Price Target of $6.00 Tetraphase Prepares for Commercialization of a Needed Antibiotic Tetraphase Pharmaceuticals, Inc. (TTPH) is Current Price $2.20 a clinical stage pharmaceutical company, 12 Month Target Price $6.00 with eravacycline as its lead candidate. It is a novel tetracycline-derived antibiotic to 12-Month Trading Range $2.05-$9.93 treat resistant and multidrug-resistant Market Capitalization (Mil) $113.50 infections, including multidrug-resistant Shares Outstanding (Mil) 51.59 Gram-negative infections. Following Avg. Daily Volume 872,642 successful IGNITE1 and IGNITE4 Phase 3 L.T. Debt (Mil) 0.00 trials in complicated intra-abdominal infections (cIAI), a New Drug Application Dividend/Yield N/A (NDA) was filed with the FDA and a Book Value P/S $2.92 Marketing Authorisation Application (MAA) was submitted to the EMA for IV NASDAQ Composite 7,218.23 eravacycline. S&P 500 2,701.33 Historical Performance and Disclosures on Page 10 - 11 Two days ago, TTPH announced an exclusive Source: QUODD+ licensing agreement with Everest Medicines Limited, a C-bridge Capital-backed biopharmaceutical company based in China, to develop and commercialize eravacycline in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore (known as the Territories). Tetraphase will receive an initial upfront payment of $7.0 million and may receive clinical and regulatory milestones of up to $16.5 million as well as a maximum of $20.0 million via achieving annual sales milestones. -
List of Marginable OTC Stocks
List of Marginable OTC Stocks @ENTERTAINMENT, INC. ABACAN RESOURCE CORPORATION ACE CASH EXPRESS, INC. $.01 par common No par common $.01 par common 1ST BANCORP (Indiana) ABACUS DIRECT CORPORATION ACE*COMM CORPORATION $1.00 par common $.001 par common $.01 par common 1ST BERGEN BANCORP ABAXIS, INC. ACETO CORPORATION No par common No par common $.01 par common 1ST SOURCE CORPORATION ABC BANCORP (Georgia) ACMAT CORPORATION $1.00 par common $1.00 par common Class A, no par common Fixed rate cumulative trust preferred securities of 1st Source Capital ABC DISPENSING TECHNOLOGIES, INC. ACORN PRODUCTS, INC. Floating rate cumulative trust preferred $.01 par common $.001 par common securities of 1st Source ABC RAIL PRODUCTS CORPORATION ACRES GAMING INCORPORATED 3-D GEOPHYSICAL, INC. $.01 par common $.01 par common $.01 par common ABER RESOURCES LTD. ACRODYNE COMMUNICATIONS, INC. 3-D SYSTEMS CORPORATION No par common $.01 par common $.001 par common ABIGAIL ADAMS NATIONAL BANCORP, INC. †ACSYS, INC. 3COM CORPORATION $.01 par common No par common No par common ABINGTON BANCORP, INC. (Massachusetts) ACT MANUFACTURING, INC. 3D LABS INC. LIMITED $.10 par common $.01 par common $.01 par common ABIOMED, INC. ACT NETWORKS, INC. 3DFX INTERACTIVE, INC. $.01 par common $.01 par common No par common ABLE TELCOM HOLDING CORPORATION ACT TELECONFERENCING, INC. 3DO COMPANY, THE $.001 par common No par common $.01 par common ABR INFORMATION SERVICES INC. ACTEL CORPORATION 3DX TECHNOLOGIES, INC. $.01 par common $.001 par common $.01 par common ABRAMS INDUSTRIES, INC. ACTION PERFORMANCE COMPANIES, INC. 4 KIDS ENTERTAINMENT, INC. $1.00 par common $.01 par common $.01 par common 4FRONT TECHNOLOGIES, INC. -
By in Vivo's Biopharma, Medtech and Diagnostics Teams
invivo.pharmaintelligence.informa.com JANUARY 2018 Invol. 36 ❚ no. 01 Vivopharma intelligence ❚ informa 2018 OUTLOOK By In Vivo’s Biopharma, Medtech and Diagnostics Teams PAGE LEFT BLANK INTENTIONALLY invivo.pharmaintelligence.informa.com STRATEGIC INSIGHTS FOR LIFE SCIENCES DECISION-MAKERS CONTENTS ❚ In Vivo Pharma intelligence | January 2018 BIOPHARMA MEDTECH 2018 DIAGNOSTICS OUTLOOK 12 22 28 Biopharma 2018: Medtech 2018: Diagnostics 2018: Is There Still A Place For Pharma The Place For Innovation Steady Progress And In The New Health Care As Value-based Health Care The Big Get Bigger Economy? Gains Momentum MARK RATNER WILLIAM LOONEY ASHLEY YEO If the beginning of 2017 was marked 2018 will be a time of transition in health 2017 was a watershed year in many by doubts around whether and how care, when biopharma’s counterparts respects, politically, economically the FDA would act with respect to in adjacent industry segments scale up and commercially for many players complex diagnostics, we enter 2018 in a radical redesign of their traditional in the medtech field. Where will the feeling that slow-moving vessel may business models. Biopharma is not opportunities lie in 2018? Will finally be turning. moving as quickly, and it confronts a breakthrough medtech innovation still strategic dilemma on how to address the have a place among providers often prospect of a much more powerful set of riding on fumes when it comes to 36 rivals in the ongoing battle to own the budgets, and is it all as bad as some patient experience in medicine. would make out? Thirty-five Years Covering Health Care: The More Things Change… 30 PETER CHARLISH A Virtuous Cycle: What The The health care industry has come a Immuno-Oncology Revolution long way in the past 35 years, although Means For Other Disease Areas in some areas very little has changed. -
Initiation Report
Company Sponsored Research Food Industry Initiation of Coverage Hunter Diamond, CFA 03/27/2019 Vivian Zhang (Equity Research Associate) Amira Nature Foods Ltd. [email protected] 1120 Avenue of Americas, 4th Floor New York, NY 10036 Attractive Valuation with Basmati Rice Representing A Large and Growing Market Price-Volume History Investment Highlights: • Amira Nature Foods (ANFI) operates within the large and growing basmati rice and specialty food market, which is expected to reach $17.74 billion by 20221. Amira Nature Foods is uniquely positioned with its global sourcing and distribution abilities and owned brands. The company targets various market segments with unique product offerings and price points, allowing it to diversify its revenue. The company operates globally on five continents, with a geographically diverse customer base. • Rice is an enormous global staple food, which enjoys favorable market dynamics, Key Statistics with Basmati rice having a large pricing premium over other varieties of rice with Share Price (As Of 03/25/2019) $1.52 Basmati rice prices additionally recently recovering from their 2015/2016 depressed price levels. The fragmented supply chain of Basmati rice has also made it difficult Valuation $4.00 for Western companies to effectively distribute it, creating a unique opportunity for 52 Week Range $0.30-$4.39 Amira. The company has a large opportunity to expand its top line, with the market for Indian Basmati rice representing $6.9 billion2 of which 70% is sold internationally. Average Daily Volume(th) 793.38 • The international opportunity is enormous, with the company looking to create a $200 Shares Outstanding (th) 46.384 to $300 million -dollar international business over the next three years (Amira averaged $320.2 million in international sales during the FY14 through FY18 period). -
Food Products
Rating |Target | Estimate Change USA | Consumer | Food Products February 14, 2018 EQUITY RESEARCH Food Products Brands Still Matter To Consumers - Do They To Investors? Key Takeaway Previously our sector thesis was that accelerating consolidation & cost cutting activity should drive earnings upside. We are adding a new element, related to brands that we believe will drive an inflection in sales growth and drive further earnings upside. The attached Brands Still Matter report, is the result of a collaborative project with Accenture & Barkley that we began 3 months ago, and forms the basis of this new “brand” element to our thesis. Key takeaways from our Brands Still Matter report are outlined below. AMERICAS Consumer preferences have not changed, and emerging brands are not tapping into newfound preferences. Taste and price remain top attributes for consumers. However, consumers have more leverage and are demanding that brands do more – i.e. meeting needs of a “holistic experience” that includes attributes such as health, trust and sustainability. Contrary to popular belief, leading brands have maintained their ground & it is important to be a leader. 60% of leading brands are growing sales and 53% are growing share. Mid-tier brands and the long “tail” is struggling. Loyalty to Leading Brands remains very high and relatively stable. Leading Brands are incredibly productive at retail. Consumer insights, brand activation and operating model agility are key to succeeding. Companies that build next-generation capabilities in consumer insights and category development, brand activation and operating model agility are likely to succeed. Cost-savings opportunity is significant and can fund next-gen capability investments. -
The Top 100 November, 2016 a List of Stocks Topping Our Custom 'Torpedo’ Screen
The Top 100 November, 2016 A list of stocks topping our custom 'torpedo’ screen. Updated monthly. GPRO GoPro, Inc. Class A Consumer Discretionary TSLA Tesla Motors, Inc. Consumer Discretionary UA Under Armour, Inc. Class A Consumer Discretionary CRC California Resources Corp Energy CRZO Carrizo Oil & Gas, Inc. Energy CWEI Clayton Williams Energy, Inc. Energy FANG Diamondback Energy, Inc. Energy GST Gastar Exploration, Inc. Energy MPLX MPLX LP Energy RSPP RSP Permian, Inc. Energy SLCA U.S. Silica Holdings, Inc. Energy AAC AAC Holdings, Inc. Health Care ABEO Abeona Therapeutics, Inc. Health Care ACAD ACADIA Pharmaceuticals Inc. Health Care ADMP Adamis Pharmaceuticals Corporation Health Care ADMS Adamas Pharmaceuticals, Inc. Health Care ADXS Advaxis, Inc. Health Care AIMT Aimmune Therapeutics Inc Health Care AKBA Akebia Therapeutics, Inc. Health Care ALDR Alder Biopharmaceuticals, Inc. Health Care ARDM Aradigm Corporation Health Care ARDX Ardelyx, Inc. Health Care ARLZ Aralez Pharmaceuticals Inc. Health Care ATRA Atara Biotherapeutics Inc Health Care BCRX BioCryst Pharmaceuticals, Inc. Health Care BLUE bluebird bio, Inc. Health Care CARA Cara Therapeutics Inc Health Care CDNA CareDx, Inc. Health Care CEMP Cempra, Inc. Health Care CERS Cerus Corporation Health Care CFMS ConforMIS Inc Health Care CLVS Clovis Oncology, Inc. Health Care COLL Collegium Pharmaceutical, Inc. Health Care CORI Corium International, Inc. Health Care CRMD CorMedix Inc. Health Care CSU Capital Senior Living Corporation Health Care DERM Dermira Inc Health Care DVAX Dynavax Technologies Corporation Health Care DXCM DexCom, Inc. Health Care EPZM Epizyme, Inc. Health Care FOLD Amicus Therapeutics, Inc. Health Care HRTX Heron Therapeutics Inc Health Care ICPT Intercept Pharmaceuticals, Inc. -
Infectious Diseases
2013 MEDICINES IN DEVELOPMENT REPORT Infectious Diseases A Report on Diseases Caused by Bacteria, Viruses, Fungi and Parasites PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Research Evolves Against Infectious Diseases with Nearly 400 Medicines and Vaccines in Testing Throughout history, infectious diseases hepatitis C that inhibits the enzyme have taken a devastating toll on the lives essential for viral replication. and well-being of people around the • An anti-malarial drug that has shown Medicines in Development world. Caused when pathogens such activity against Plasmodium falci- For Infectious Diseases as bacteria or viruses enter a body and parum malaria which is resistant to multiply, infectious diseases were the current treatments. Application leading cause of death in the United Submitted States until the 1920s. Today, vaccines • A potential new antibiotic to treat methicillin-resistant Staphylococcus Phase III and infectious disease treatments have proven to be effective treatments in aureus (MRSA). Phase II many cases, but infectious diseases still • A novel treatment that works by Phase I pose a very serious threat to patients. blocking the ability of the smallpox Recently, some infectious pathogens, virus to spread to other cells, thus 226 such as pseudomonas bacteria, have preventing it from causing disease. become resistant to available treatments. Infectious diseases may never be fully Diseases once considered conquered, eradicated. However, new knowledge, such as tuberculosis, have reemerged new technologies, and the continuing as a growing health threat. commitment of America’s biopharma- America’s biopharmaceutical research ceutical research companies can help companies are developing 394 medicines meet the continuing—and ever-changing and vaccines to combat the many threats —threat from infectious diseases. -
Background of the Corporate Debtor*
Background of the Corporate Debtor* Amira Pure Foods Pvt Ltd (‘Amira’) is a major international producer of packaged Indian specialty rice, with sales in over 60 countries. AMIRA offers an extensive portfolio of brands that have been carefully developed to appeal to local markets around the world. Customer tastes and expectations have been finely segmented to deliver authentic flavours that go well with a variety of popular cuisines. Consumer palettes across the market segments have been well researched and adapted to suit the requirements of various trade channels. AMIRA has expanded its product line into snacks, Ready-to-eat and organic food products. Founded in 1915, AMIRA group in the past six years, transitioned from a family-managed company to a professionally run international food company, under the leadership of the fourth generation. In October 2012, AMIRA Nature Foods Ltd (parent company of Amira Pure Foods Pvt Ltd) completed an initial public offering. Its stock trades on the New York Stock Exchange (NYSE) listed under the ticker symbol “ANFI”. They generate the majority of their revenue through the sale of Basmati rice, premium long-grain rice grown only in certain regions of the Indian sub-continent, under their flagship AMIRA brand as well as under third-party brands. HISTORY WITH FARMERS Company has worked for decades with farmers in parts of India where basmati rice is grown. They work to educate them in the best techniques of agriculture, and share with them their technology for mapping and weather analysis. The result is that Amira have a regular and a large supply of the highest quality product. -
Say on Pay Results (As of September 5)
THIS REPORT CAN BE ACCESSED AT HTTP://WWW.SEMLERBROSSY.COM/SAYONPAY NOTE: THIS WILL BE OUR FINAL SAY ON PAY UPDATE FOR 2012. WE WILL ISSUE A FULL REPORT PROVIDING RESULTS FOR THE ENTIRE 2012 PROXY SEASON IN JANUARY 2013. PLEASE CONTINUE TO VISIT OUR SAY ON PAY BLOG FOR UPDATES. SAY ON PAY RESULTS 2012 RUSSELL 3000 SEPTEMBER 5 2012 SAY ON PAY RESULTS: RUSSELL 3000 SHAREHOLDER VOTING SUMMARY OF FINDINGS 2012 Vote Results (n=2,025) 2 The majority of companies continue to pass Say on Pay in 2012 with substantial shareholder support: — 1,466 companies (72%) passed with over 90% support — 381 companies (19%) passed with between 70% and 90% support — 125 companies (6%) passed with between 50% and 70% support — 53 companies (2.6%) in the Russell 3000 have failed Vote of the Week McKesson received a vote of 62%, a decline of 8% from 2011, amidst criticism from shareholders and 3 their advisors over high relative CEO pay and retirement benefits Vote Results by Industry Health Care companies have received proportionally less support than other industries, while 4 Consumer Staple and Financial companies have received the most support Vote Results and Market Value 5 There does not appear to be a strong correlation between a company’s market value and Say on Pay vote result How Vote Results Changed in 2012 6 Companies below 70% in 2011 have generally received increased vote support in 2012: — 26 of 30 companies that failed in 2011 have passed in 2012 — Companies between 50‐70% in 2011 have improved by an average of 13% in 2012 Vote results for companies